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Abstract
Caveolae are 50- to 100-nm cholesterol and glycosphingolipid-rich flask-shaped
invaginations commonly observed in many terminally differentiated cells. These
organelles have been described in many cell types and are particularly abundant in
endothelial cells, where they have been involved in the regulation of certain signaling
pathways. Specific scaffolding proteins termed caveolins, along with the more
recently discovered members of the cavin family, represent the major protein
components during caveolae biogenesis. In addition, multiple studies aimed to
investigate the expression and the regulation of these proteins significantly
contributed to elucidate the role of caveolae and caveolins in endothelial cell
physiology and disease. The aim of this review is to survey recent evidence of the
involvement of the caveolar network in endothelial cell biology and endothelial cell
dysfunction.
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1 | INTRODUCTION
Lipid rafts (LRs) and caveolae are distinct plasma
membrane microdomains with a unique lipid composition
present in a variety of different cell types. Unlike LRs,
whose existence remains elusive in living cells, caveolae are
50-100 nm flask-shaped invaginations clearly detectable by
electron microscope. During the last two decades both LRs
and caveolae have been involved in a variety of biological
processes including cell growth, proliferation, apoptosis,
angiogenesis, and cancer. The shape as well as the
biogenesis of caveolae depend mostly on the presence of
small scaffolding proteins belonging to the caveolin gene
family that includes caveolin-1, caveolin-2, and caveolin-3.
These scaffolding proteins contribute to the assembly of a
complex molecular platform that facilitates the integration
of a variety of signaling molecules as well as the regulation
of certain transmembrane signaling events. In addition, the
presence of caveolin represents a useful molecular marker
for the isolation of caveolae-enriched membranes from cells
cultivated in vitro, that is central for the investigation of the
role of these organelles in cellular functions both in
physiological and pathological conditions. In this review,
we mainly focus on recent findings that support the role of
caveolae and caveolin proteins in the regulation of
endothelial cells (EC) functions, with emphasis on potential
application in angiogenic-based therapy.
2 | BIOGENESIS OF LIPID RAFTS
AND CAVEOLAE
Our view of the “fluid mosaic” model of the plasma
membrane illustrated more than 40 years ago, that describes
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the cell surface as a low energy structure with randomly
dispersed molecules,1 has been deeply revised through the
years. Starting from the late 80s an increasing number of
evidence have revealed the existence of specific plasma
membrane domains particularly enriched in glycosphingoli-
pids, gangliosides, and cholesterol termed LRs, that have
soon revealed an interesting talent to sequestrate a variety of
structural and signaling molecules, leading to a fine
regulation of downstream mechanisms in different cell
types.2–6 LRs are detergent-resistant non invaginated, flat,
plasma membrane microdomains containing a unique
combination of glycosphingolipids, and cholesterol.7,8 Two
main types of LRs are described based on the presence of the
cholesterol binding protein caveolin-1.9 LRs that contain
caveolin-1 can promote the formation of clearly detectable
flask-like invaginations termed caveolae. In contrast, LRs that
do not contain caveolin-1 remain as presumably flat
undetectable structures on the plasma membrane. However,
in certain cell types such as neurons and lymphocytes, the
presence of LRs along with the expression of caveolin-1 do
not result in the formation of caveolae, raising the question
about the function of caveolin-1 in these cell types.10
Caveolae were initially described in the early 50s by Palade
and Yamada as omega-shaped membrane invaginated
“smooth” (noncoated) vesicles of 50-100 nm in size.11,12
After their discovery, caveolae have been identified in a
variety of cell types, including smooth muscle cells, EC,
fibroblasts and adipocytes, challenging many investigators to
explore their functional significance in cell functions. Early
studies, almost exclusively based on morphological observa-
tion, reinforced the earliest hypothesis, anticipated by Palade
of caveolae as structures involved almost exclusively in
transcellular trafficking of molecules across the EC barrier.13
Other well-known functions of caveolae include cholesterol
transport,14,15 potocytosis,16 and endocytosis.17 Structurally,
caveolae display different level of organization, forming
grape-like clusters, rosettes, membrane-bound or detached
vesicles and tubule-like structures, clearly detectable by
electron microscope in different cell types.18 However, only
with the discovery of the involvement of caveolae in the
sequestration and uptake of small molecules16 and later with
the identification of caveolin-1.19–21 as the first molecular
marker used as a convenient tool for the isolation of caveolae-
enrichedmembranes,22–26 the research in this field has greatly
boosted. Caveolin-1 was the first member of this family to be
identified,19 followed by the discovery of caveolin-227 and
caveolin-3.28 Caveolin-1 is expressed in most cell types such
as adipocytes, epithelial cells, and fibroblasts where it is
typically found co-expressed with caveolin-2.27,29 Caveolin-
3, which appears shorter but functionally and structurally
similar to caveolin-1, is known to be muscle specific and
expressed in skeletal, cardiac and smooth muscle cells.28
Unlike caveolin-1 and caveolin-3, caveolin-2 appears
incapable of forming caveolae and is usually found
sequestered and degraded in the Golgi apparatus in the
absence of caveolin-1.27,30,31 Caveolins contain three distinct
regions including a cytosolic N-terminal domain, a trans-
membrane domain and a hydrophilic C-terminal domain.
Although the C-terminal domain has been demonstrated to be
a site of palmitoylation, the significance of this modification
is debated32–34 and this modification seems not essential for
proper localization of caveolins into caveolae. While the
contribution of caveolin-1 is crucial for the formation of
caveolae, recent studies identified a novel family of proteins
termed cavins that actively participate to the biogenesis of
caveolae, and specifically contribute to membrane curvature
of these organelles.35 Therefore, the persistence of caveolin
and cavin oligomers is essential for the stability of plasma
membrane bound caveolae. However, this association can be
modulated by a variety of stimuli that destabilize caveolae and
usually terminate with internalization of the caveolin
proteins. Four different cavin proteins have been identified
so far with different cellular distribution. Cavin 1/Polymerase
I and transcript release factor (PFTR/Cav60/Cavin) appears to
show an overlapping expression pattern with caveolin-1 and
is a key molecule for caveolae biogenesis.36,37 Cavin 2,
encoded by the Serum Deprivation Response (SDPR) gene,
cavin-3 (PRKCDBP) and the muscle-specific cavin 4
(MURC) are all also involved in the formation of
caveolae.38–40 An additional molecule, termed EHD2
belonging to the Eps15 homology domain (EHD) proteins,
appears to be specifically involved in the regulation of
membrane dynamics.41,42 To this regard, it has been recently
demonstrated that due to its ability to change its structural
conformation in the presence of ATP, EHD2 can switch from
an active membrane-bound conformation to an inactive
soluble form, regulating caveolae association to the plasma
membrane.43 Hence, the caveolar network represents un-
doubtedly a molecular platform that has been stimulating the
interest of many investigators for years in seeking of the
physiological and pathological significance of these organ-
elles in many fields of research, frommembrane biogenesis to
diseases.
3 | THE CONTRIBUTION OF THE
CAVEOLAR NETWORK TO CELL
SIGNALING
There is increasing evidence that demonstrate the involve-
ment of the caveolar network in cell responses to incoming
chemical and mechanical stimuli as well as in the regulation
of the downstream signal transduction cascades. The caveolar
network can function as a molecular switch that can activate,
inhibit or modulate specific cellular functions in a variety of
cell types depending on the precise interactions occurring
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between signaling molecules within the organelle itself. With
the discovery of the caveolin gene family, many evidence
have been collected on the involvement of caveolae and
caveolin proteins in cell signaling.44–47 It has been
demonstrated that mice carrying a single deletion of any of
the caveolin genes resulted vital and fertile, whereas the
double knock-out of caveolin-1 and -3 developed severe
cardiomyopathy and inflammation,48 raising interest on the
pathological role of these organelles. On the other hand, the
role of caveolin-2 in this scenario is less clear and the protein
appears to play a regulatory role for caveolae stability.49
Therefore, the information concerning the involvement of
caveolins in signal transduction mostly come from studies
carried out on caveolin-1 and have focused to investigate how
the proficiency of this protein to bind and sequestrate a variety
of signaling adapters can regulate downstream pathways.
This scaffolding talent of caveolin-1 led to the concept of the
“caveolae signaling hypothesis”23 that predicts the existence
of interactions between the 20-amino acid segment in the
caveolin scaffolding domain (CSD, aa 82-101)50 and an
aromatic-rich caveolin binding motif (CBM) on associated
signaling partners.51 Binding to CSD is sufficient to inhibit
the activity of many signaling molecules such as G-proteins,
Src-like kinases, eNOS, H-Ras, and EGFR.52–54 In vivo
studies supported the idea that caveolins can modulate signal
transduction independently of their structural role carried out
during caveolae formation,55 encouraging many groups to
investigate more in deep the contribution of caveolins to
specific cellular mechanisms. Different types of membrane
bound and intracellular receptors involved in signal transduc-
tion, such as G protein-coupled receptors (GPCRs) and
receptor tyrosine kinases (RTKs), have been found localized
into caveolae or to interact with caveolins within the
endothelial compartment.56 Some GPCRs appear more
dependent on the integrity of LRs whereas other members
of the family have been found to interact with caveolins,
suggesting that caveolar platform as well as LR micro-
domains contribute to their function. CCR5 is a chemokine
receptor belonging to GPCRs family involved in the
modulation of immune response triggered by chemokines.
The contribution of functional LR microdomains to proper
activation of CCR5 signaling has been demonstrated by the
use of cholesterol depleting agents such as hydroxypropyl-β-
cyclodextrin, in human CD4+ lymphoblasts,57 that affects
CCR5 ligand ability and impairs the activation of cell
signaling. Notably, even though the majority of CCR5 resides
within raft microdomains, the receptor can function in non-
raft domain as it happens for HIV entry into the cell.58 Other
studies have also suggested the contribution of the caveolar
network during the internalization of GCPRs. For example,
by using a labeled cholera toxin bound to ganglioside GM1, it
has been shown the direct contribution of caveolae and
caveolin-1 during the endocytosis of the adenosine receptor
A1 in smooth muscle cells.59 Based on the role of adenosine
during ischemia and inflammation and the expression of
adenosine receptors in EC,60 the caveolar network may
represent a potential target in the treatment of damaged
tissues. In addition, other GCPRs such as the endothelin type
A (ETAR) and B (ETBR) receptors were found localized into
LRs/caveolae in rat peritubular smooth muscle cells.61 To this
regard, these authors demonstrated that the integrity of these
plasma membrane microdomains is essential only for ETB-
but not for ETA-mediated Ca2+ signaling, emphasizing the
role of caveolae during the spatio-temporal coordination of
NAADP (Nicotinic acid adenine dinucleotide phosphate)-
dependent Ca2+ release through ETBRs. Other authors
reported that, in EC, only ETBR resides within caveolae
from which it is internalized upon administration of
endothelin. These observations were supported by the use
of specific ETBR (but not ETAR) inhibitors that prevented
ET-induced budding of caveolae.62 RTKs represent a large
family of molecules also involved in signal transduction. The
different types of RTKs are included into about twenty
different RTK classes and many of them have been found
either localized into caveolae or to interact with caveolin-1.63–
67 In addition, vascular endothelial growth factor (VEGF),
angiopoietin, PDGF and Ephrin receptors, all belonging to the
RTK family, have been found mostly expressed in EC where
they play a central role during the angiogenic process.68 There
is no much information regarding the contribution of the
caveolae network during ligand-gated ion channels signaling
specifically in the endothelium. However, it has been reported
the compartmentalization of P2 × 7R into caveolae and its
colocalization with caveolin-169 in EC, even though the
significance of this interaction is far from being elucidated.
4 | CAVEOLAE AND CAVEOLINS IN
ENDOTHELIAL CELLS
The generation of caveolin null mice made it possible to
investigate more in deep the significance and the contribution
of both the caveolar system and caveolins to the animal
physiology.70–73 In cultured EC, caveolin-1 functions as a
major scaffolding protein that helps to sequestrate key
signaling molecules, such as TNFR1 and TNF-alpha
converting enzyme (TACE), into caveolae.64,74–76 During
the past two decades, the study of caveolae and caveolin
proteins has generated great attention especially because of
their involvement in pathological conditions.77,78 Caveolins,
and in particular caveolin-1, have been involved in a variety
of different cellular mechanisms from membrane trafficking
to cell migration, angiogenesis, and cancer. Besides adipo-
cytes, where caveolae are particularly abundant, EC show an
overall high number of caveolae, mostly observed in the
microvascular continuous endothelium, but excluded in
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fenestrated endothelium, and sinusoids.79 The high abun-
dance of caveolae in EC has further stimulated the
investigation of these organelles in EC biology, originally
started with the studies of Palade and Bruns in the vascular
endothelium in the late 60s.80,81 A variety of caveolin-1
containing vesicles are usually found in EC and, in addition to
characteristic non-coated flask invaginations of the plasma
membrane, endothelia appear to contain different caveolin-1
positive structures such as tubular channels or floating
vesicles detached from the plasmamembrane.18 In addition to
their role in trafficking of molecules across the endothelial
barrier, caveolae, and caveolins can function as mechanor-
eceptors during EC response to extracellular hemodynamic
forces such as the shear stress. Indeed, the endothelium does
not exclusively function as a physical barrier between blood
and the blood vessel wall but it is normally exposed to
hemodynamics forces of different amplitude that can
contribute to the development of vascular conditions such
as inflammation and atherosclerosis. Therefore, EC have
developed the ability to convert these mechanical cues into
precise signal transduction mechanisms. Several molecular
receptors have been proposed to play an active role during
response to mechanical and hemodynamic forces in EC.
These include integrins, VEGFR2, GPCRs and purinergic
receptors.82–85 It has been reported that the exposure of EC to
shear stress or stretch, affects the number as well as the
distribution of caveolae86,87 indicating that these organelles
may play a crucial role during EC dysfunctions.88 Notably,
the number of caveolae, but not necessarily the level of
caveolin-1, decreases in primary EC, forcing researchers to
employ EC lines that maintain unvaried levels of both
caveolae and caveolin-1.75 These observations are also in
accordance with recent findings indicating that caveolin-1
deficient cells undergo premature senescence in fibroblasts
due to mitochondrial dysfunction.89 Since their first descrip-
tion, significant advances have been made in the understand-
ing of the role of the caveolar network in EC functions and the
discovery of the caveolin family of proteins has further
fostered the investigation of the involvement of the caveolar
network both in physiological and pathological models.
5 | CAVEOLIN AS A NEGATIVE
REGULATOR OF eNOS ACTIVITY
Undoubtedly, one of the best-known function that links
caveolin-1 to EC functions refers to the ability of this
scaffolding protein to inhibit the activity of endothelial nitric
oxide (eNOS).90,91 eNOS was among one of the first proteins
found associated to caveolae92 where it binds to the caveolin
scaffolding domain (CSD, aa 82-101) and to a lesser extent to
the C-terminal region (aa 135-178)93 of caveolin-1. Following
myristoylation of its N-terminal glycine and palmitoylation of
the Cys15 and Cys26 residues, eNOS is kept inactive into
caveolae, associated to caveolin-1. Only in the presence of
specific stimuli this interaction is lost, activating downstream
signaling (Figure 1). In addition, the interaction between
caveolin-1 and eNOS takes place into caveolae but not into
LRs, demonstrating the distinct spatial regulation of caveolae-
and rafts-dependent signaling.94 In vivo studies confirmed the
correlation between the loss of caveolin-1, the increased level
of NO and the decreased arterial myogenic tone in KO mice,
predicting a direct involvement of caveolin-1 in the control of
blood pressure. However, whether caveolin-1 depletion is
beneficial to control blood pressure is still controversial and
only few studies demonstrated a decrease of systemic blood
pressure in caveolin-1 KO mice.70,95–97 These conflicting
results may be explained by the activation of compensatory
mechanisms in response to chronic production of NO in
caveolin-1 KOmice, that are hard to investigate. However, the
use of cavnoxin, a cell-permeable peptide bearing a specific
mutation that disrupts the interaction between eNOS and
caveolin-1,98 both lowered blood pressure and reduced the
myogenic tone in vivo. Based on the relationship that links
eNOS to calmodulin activation, both caveolae and caveolin-1
have been proposed as potential candidates involved in
FIGURE 1 Contribution of caveolin-1 to eNOS and VEGFR2 activity. A, in non-stimulated cells, binding of caveolin-1 to eNOS into
caveolae, keeps the enzyme in its inactive form. In the same compartment caveolin-1 binds to and sequestrate VEGFR2. B, In the presence of
specific stimuli (eg VEGF) binding between caveolin-1 with eNOS or VEGFR2 is lost, favoring downstream signaling
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calciummobilization, both from the extracellular compartment
and from internal stores. Notably, calmodulin activates eNOS
by displacing its interaction with caveolin-1. Although
caveolae have been proposed to be involved in the regulation
of intracellular calcium concentration and calcium dependent
signal transduction,99 and caveolin-1 has been found determi-
nant for calcium entry into the cell,100,101 the precise
involvement of the caveolar platform in these mechanisms
in endothelium will require further studies.
6 | CAVEOLINS AND ENDOTHELIAL
PROGENITORS CELLS (EPCs)
Blood vessel development in the embryo takes place through
two specific mechanisms, namely vasculogenesis or the
differentiation and growth of blood vessels from mesodermal
derived hemangioblasts and angiogenesis, which ensures
further development and remodeling of the primitive vascular
network. On the other hand, it is now widely accepted that
new vessel formation can arise from differentiating EPCs,
residing in the bone marrow.102 Since their first appearance in
the literature,103 EPCs contributed to revise the original
concept of vasculogenesis as a mechanism that exclusively
takes place in the embryo. Differentiation of EPCs can,
indeed, occur also in the adult and may represent a key
mechanism during reendothelialization and neovasculariza-
tion after injury as well as adult vasculogenesis.104–107 EPCs
have been described as cells expressing VEGFR2, CD34 and
CD133, although there is still considerable debate regarding
their nature. Many groups have focused their attention on the
role of EPCs and their potential contribution to therapeutic
angiogenesis.108–111 Among known molecules involved in
postnatal vasculogenesis, Stromal cell-Derived Factor-1
(SDF-1) and VEGF represent crucial molecules during the
recruitment of EPCs.112 Although highly debated, some
evidence suggesting a role of the caveolar network during
EPCs recruitment in the bone marrow, have stimulated the
investigation of caveolae/caveolins during postnatal vasculo-
genesis.113,114 The recruitment of EPCs from bone marrow to
the peripheral blood appears strictly dependent on the
expression of VEGFR2, which resides into caveolae, SDF-
1, and VEGF itself.115 The contribution of caveolin-1 to EPCs
recruitment has been recently reported in caveolin-deficient
mice (Cav−/−). This study demonstrated that defect in
caveolin-1 expression impairs internalization of CXCR4
receptor induced by SDF-1 therefore affecting the recruitment
of EPCs from bone marrow.116 Therefore, understanding the
involvement of caveolae/caveolin-1 during the recruitment of
EPCs can be central for the development of potential
therapeutic applications aimed to induce postnatal vasculo-
genesis. In addition, recent findings have suggested that
NAADP-induced calcium mobilization from intracellular
stores promotes EPC proliferation,117 suggesting a role of
NAADP-induced signaling during neovascularization.118
Interestingly, this mechanism is strictly linked to the caveolar
network and increasing interest has developed concerning the
role of caveolae as potential sites for Ca2+ entry.99,119 In
addition, studies in the literature suggest the existence of two
different EPC populations, named early EPCs (eEPCs) and
Outgrowth endothelial cells (OECs) that show a different
behavior when cultured in vitro. Interestingly, among a
number of different markers evaluated, OECs but not eEPCs
express high level of caveolin-1 in addition to VE-cadherin
and Von Willebrand Factor.106 However, whether the high
expression of caveolin-1 in OECs has a biological signifi-
cance is not known. Nevertheless, since OECs, rather than
eEPCs, look more similar to EC and possess intrinsic
angiogenic features, they are potential candidates for
developing specific therapies for vascular based diseases.
Notably, the inhibitory function of caveolin-1 seems to
correlate with an increasing expression of stem cell markers in
different organs of caveolin-1 KO mice, suggesting a role of
caveolin-1 in stem cell differentiation.120
7 | THE CAVEOLAR NETWORK IN
ANGIOGENESIS
The formation of new capillary blood vessels, termed
angiogenesis, is regulated by a precise balance of growth,
and inhibitory factors in healthy tissues. Early during embryo
development, mesoderm-derived stem cells give rise to
hemangioblasts that differentiate into hematopoietic stem
cells (the precursors of blood cells), and angioblasts (the
precursors of the blood vessels).121 The proliferation and
differentiation of angioblasts give rise to EC and endothelial
tubes during vasculogenesis.122,123 VEGF is among the key
factors involved in the differentiation of angioblasts. To this
regard, it has been demonstrated that the lack of a single
VEGF allele is sufficient to induce severe defects in the
development of the cardiovascular system leading to death
before birth. A similar scenario was observed following the
disruption of the VEGF receptor genes.124,125 The subsequent
expansion of this primitive vessel network is carried on during
angiogenesis occurring as the result of endothelial sprouting
and microvascular growth. Recent studies focused on the
development of the retinal vasculature have demonstrated that
the expression of plexin-D1 mRNA is rapidly downregulated
in the central vascular plexus, where sprouting starts, but
remains higher in the actively sprouting vessels. These data
suggest a dynamic expression as well as an active role of
plexin-D1 in the discrimination between tip and stalk cells
during vessel growth in response to VEGF.126 However, in
the adult the scenario changes because post-natal EC are
relatively quiescent during adulthood, when physiological
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angiogenesis is mainly limited to few processes such as
wound healing, the uterine cycle (menstruation) and during
the development of the placenta throughout the course of
pregnancy. Therefore, abnormal development of new blood
vessels in the postnatal life is often associated to an
imbalanced expression between stimulators and inhibitors
of vessel growth that can result in an excessive (switched on)
or insufficient (switched off) angiogenesis. Many pathologi-
cal conditions, including ocular diseases, inflammatory
disorders, cancer and metastasis are well known examples
of switched on angiogenesis, whereas in other conditions such
as ischemic heart disease, the angiogenic switch is inade-
quate, resulting in EC dysfunction.127 Angiogenesis typically
takes place under hypoxic condition or in the presence of pro-
angiogenic factors such as VEGF128–130 which acts by
increasing vascular permeability and promotes EC migration
by weakening inter-EC contacts, destabilizing the pre-
existing vessels. In the presence of angiogenic stimuli, EC
secrete and activate many proteolytic factors, such as matrix
metalloproteases (MMPs), that induce the release of growth
factors normally trapped in the extracellular matrix (ECM),
facilitating EC migration, and their further development into
new blood vessels during sprouting angiogenesis. The growth
of new capillaries requires the presence of a specialized
endothelial “tip cell” that drives the outgrowing vessels by
extending motile filopodia toward gradients of angiogenic
factors.131 A second cell type termed “stalk cell,” endowed
with a high proliferative aptitude, follows the tip cell, and
guarantees the elongation as well as the lumenization of the
new vessel. The notch signaling mainly contributes to
determinewhich cells will become tip or stalk cells. Basically,
VEGF-induced Delta-like-4 (Dll-4) expression by tip cell
activates the notch signaling and dampens VEGFR2 expres-
sion in stalk cells, reducing their migratory activity, contrary
to what happens to tip cells.132,133 The final step in the
formation of new blood vessels requires their stabilization
through the recruitment of periendothelial pericytes and
smooth muscle cells.134
7.1 | The caveolar network and the angiogenic
machinery
Among the VEGF receptors, VEGFR2, the major player of
VEGF-induced angiogenesis, and VEGFR3 have been found
localized into caveolae where they interact with caveolin-
1.135–138 Interestingly, in EA.hy926 EC line, the silencing of
caveolin-1 by RNAi has been demonstrated to affect cell
migration, MMPs activity and VEGF-induced angiogenesis
in vitro.139 In addition, a variety of proteins that participate in
VEGF signal have been shown localized into caveo-
lae,75,140,141 and other studies demonstrated that both
stimulators and inhibitors of angiogenesis affect the expres-
sion of caveolins.45,142 Angiogenesis activators, such as
VEGF, basic fibroblast growth factor (bFGF), and HGF have
been reported to reduce caveolin-1 expression. By contrast,
this effect is reversed in the presence of angiogenesis
inhibitors such as angiostatin, thalidomide and others.142 In
addition, in vivo studies have shown that bFGF-induced
angiogenesis was strongly compromised in caveolin-1 KO
mice, compared to the wild-type mice.143 These data support
the idea that angiogenic stimuli require the displacement of
adaptor molecules from their inhibited status within the
caveolar network. The presence of a functional caveolar
network has been found paramount during VEGF-induced
ERK activation as well as for ensuring endothelial cell
migration following the dissociation of VEGFR2 from the
inhibitory effect of caveolin-1.64 More recently, it has been
suggested that in EC caveolin-1 contributes to the assembly of
a complex IL1β-induced proangiogenic molecular platform,
consisting of Tumor Necrosis Factor Receptor 6 (TRAF6),
p38-MAPK, and MAPK-activated protein kinase 2. Notably,
most of these molecules had been already associated with the
caveolae network in EC.75,144 Unusual angiogenic process
takes place during abnormal blood vessel growth in tumors in
response to an unconventional concentration of angiogenic
factors in the presence of a hypoxic environment.145 Tumor
vessels commonly show abnormalities such as tortuosity,
fragility, lack of pericytes, tendency to bleeding, exudation
and elevated expression of VEGF and VEGFR2.146 Non-
physiological concentration of oxygen can contribute to the
rearrangement of the plasma membrane proteome and of its
endocytic activity via caveolin-1 dependent mechanisms.147
It is well known, indeed, that the finely regulated endocytic
mechanism as well as the expression of endocytosis
associated proteins are frequently affected during malignant
transformation and can be regulated by oxygen level.148
Therefore, caveolin-1 may play a key role in the regulation of
endocytosis within the hypoxic environment, making this
protein a potential therapeutic target during malignant
transformation.
7.2 | Pro- and anti-angiogenesis function of
caveolin
Because of the compartmentalization of VEGFR2 into
caveolae and its association with caveolin-1, the presence of
a functional caveolar network appears to be crucial for
VEGF-induced signaling, both under physiological and
pathological conditions. Supporting this scenario, it is worth
to mention that VEGF functions by disrupting the
interaction between caveolin-1, and VEGFR2 within
caveolae,64 leading to the activation of downstream
signaling. This endogenous inhibitory function of caveo-
lin-1 results also evident in its ability to regulate cell
polarity, directional movement and cell migration of
primary EC, a key step during blood vessel growth in
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response to VEGF. These data demonstrate that not only the
expression but even the precise distribution of caveolin-1
within the cellular compartment contributes to determine
cell polarity and influences cell functions.149 Early evidence
regarding the pro-angiogenic role of caveolin-1 date back to
the early 2000s, when it was demonstrated that antisense
oligodeoxynucleotides against caveolin-1 reduced the
number of detectable caveolae and suppressed capillary-
like tube formation.150 Afterwards, Liu et al. demonstrated
that the expression of caveolin-1 increased during EC
differentiation, reaching its maximum level just before to
the formation of capillary-like tubules. Interestingly, when
caveolin-1 was overexpressed, tube formation resulted
dramatically accelerated. On the contrary, when caveolin-
1 was downregulated, the number of capillary-like tubules
was reduced by 10- folds and over.151 These findings were
further proved in vivo, where the neovascularization of
caveolin-1 KO mice injected with a matrigel plug
supplemented with bFGF was strongly reduced.143 More
recently Madaro et al139 investigated the role of caveolin-1
at morphological and functional level in EC and demon-
strated that silencing of caveolin-1 by RNAi not only
induced morphological changes of EC but also reduced cell
migration and tubulogenesis in response to VEGF. This
talent of caveolin-1 to regulate angiogenesis might be
associated to the inhibition of eNOS, which is commonly
found associated to caveolin-1 in EC. Indeed, studies
performed in both caveolin-1 and eNOS KO mice
demonstrated the impairment of cell migration, cell
sprouting from aortic rings, tube formation and tumor
growth.152 Nevertheless, in addition to its pro-angiogenic
function in EC, both in vitro and in vivo studies support the
antiangiogenic role of caveolin-1. For example, studies
from Bauer and collaborators demonstrated that VEGF-
mediated angiogenesis is reduced by 40% in transgenic mice
overexpressing caveolin-1 in endothelium compared with
control littermates.55 Another study performed using a
caveolin-based plasmid delivery corroborates the antiangio-
genic effect of caveolin-1 in microvascular density and
tumor growth.153 These authors demonstrated that VEGF-
induced EC migration and tube formation were strongly
reduced in cells overexpressing caveolin-1 and similar
results were obtained with the inhibitor of eNOS, confirm-
ing the key importance of caveolin-1/eNOS interaction in
the regulation of EC functions. Additional findings
supporting the inhibitory activity of caveolin during EC
functions, come from an in vitro study showing that
overexpression of caveolin-1 in HUVEC reduced VEGF-
induced activation of p42/44 MAP kinase.154 This contro-
versial function of caveolin-1 may be due to different
extracellular environments regulating specific cell func-
tions. Therefore, distinct responses to the same cue may
activate different signaling pathways, depending on the
specific location and distribution of surface receptors (eg
inside or outside caveolae). To this regard, it shouldn’t be
overlooked the fascinating role of caveolae as mechano-
sensing structures that cells can employ to adapt to
particular extracellular conditions.155
8 | FUTURE PERSPECTIVES
Since their discovery more than 50 years ago, caveolae have
been linked to many cellular processes from vesicular
transport and cholesterol homeostasis to the onset of
pathological conditions. The identification of the caveolin
gene family in the late 90s provided researchers an innovative
molecular tool to isolate caveolin enriched membranes thus
opening new approaches to investigate the role of the caveolar
network in cellular functions. This explains why the
investigation in this field has greatly boosted over the years.
Among the three caveolin proteins, caveolin-1, the main coat
protein of caveolae, appears to be themajor player involved in
a variety of cellular processes mostly via its CSD through
which the protein regulates the activity of key signaling
molecules. Although the contribution of the caveolar network
has been undoubtedly involved in some pathological
conditions (Figure 2), the contribution of caveolins to the
onset of cancer and tumor angiogenesis remains still
controversial. This is mostly due to the great variability
among the different kinds of tumors and to the high
heterogeneity of tumor microenvironments. Undoubtedly,
tumor cells show altered caveolae as well as changes or loss of
caveolin expression, a condition that generates atypical cell
signaling. In addition to the structural role, endothelial
caveolin-1 and caveolae have been shown to play an
important role in angiogenesis by regulating the activity of
key molecules as well as downstream signaling events.
Despite the ever-growing reports of the involvement of
FIGURE 2 Summary of the most common processes regulated
by the presence of the caveolar network
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caveolae and caveolins in endothelial cell functions, many
aspects concerning their contribution to angiogenesis and
angiogenesis based diseases remain open. The generation of
caveolin-1 null mice has greatly improved our knowledge of
the involvement of the caveolar network in cell functions.
However, in most cases the molecular details of disrupted
signaling and the intracellular fate of signaling partners in the
absence of caveolin-1 remain unclear. Notably, a bioactive
secreted form of caveolin-1 has been also reported to regulate
cell survival and tumor progression in prostate cancer.149
However, the specific role of the soluble form of caveolin-1 in
other cell functions, of its trafficking into the extracellular
space and its possible interactions with other signaling
molecules, represent a potential interest in the field of
vascular pathology and tumor angiogenesis. Finally, since the
involvement of caveolin-1 in the regulation of the Notch
signaling, it is worth investigating more in detail the possible
contribution of this protein to the early steps of the angiogenic
process that determines, for example, the specification of tip
and stalk cells.
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